Who owns intercept pharmaceuticals Contact For more information about Intercept, please contact: For media: media@interceptpharma. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. Food and Drug Administration (FDA Faceless private equities and hedge funds control the firms essential to our health and survival. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 investors@interceptpharma. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after acquiring an additional 135,003 shares during the last quarter. 3k $30k Intercept Pharmaceuticals | 64,412 followers on LinkedIn. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic Intercept Pharmaceuticals | 64,368 followers on LinkedIn. NEW YORK, April 6, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. 575 Follower:innen auf LinkedIn. Understand the metabolic effects of FXR. AbbVie Inc. 561 follower su LinkedIn. S. Bile ducts are tube-like structures that carry bile from the liver to the intestine to help with the digestion of food. The 17-year-old company has never been Manufacturing and sale of pharmaceuticals in the women's health and prostate cancer area: Manufacturing and sale of pharmaceuticals in the urology area: R&D, manufacturing and sale of pharmaceuticals in the pediatrics and respiratory rare diseases area: Capital: US$1,000: US$1: US$0: US$0: US$0: US$0: Date of Establishment : July 2009: November To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. ICPT soared 79. 9, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. This net worth estimate does not reflect any other investments that Dr. When bile Continued Alfasigma, one of Italy's leading pharmaceutical companies, has agreed to acquire Intercept Pharmaceuticals, a biopharmaceutical company focused on rare and serious liver diseases, for $794 million in a transaction that will expand Alfasigma’s footprint in the United States and strengthen its pipeline. Continue Intercept Pharmaceuticals | 60,739 followers on LinkedIn. (ICPT) Shareholder Composition. com Source: Intercept Pharmaceuticals, Inc. , Oct. com or connect with the Company on LinkedIn , Threads and X (formerly MORRISTOWN - Intercept Pharmaceuticals, Inc. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced the first peer-reviewed publication of 'COBALT: A Confirmatory Trial of Obeticholic Acid in NEW YORK, Aug. Intercept Pharmaceuticals Inc. 67%) don't compete against each other at this point, but that just might change in the not-too-distant future. m. /PRNewswire/ -- Intercept Pharmaceuticals, Inc. U. Keith Speights owns shares of Intercept Pharmaceuticals | 57. announced an agreement to acquire Intercept for $19. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization The Seller owns and carries on the Business. (Nasdaq Intercept provides this link as a service to its website visitors. Alfasigma USA, Inc William Wallace is the Chief Information Officer at Intercept Pharmaceuticals based in Morristown, New Jersey. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 Intercept owns the commercial rights to Ocaliva in the U. DALY. (NASDAQ:ICPT), it is important to understand the ownership structure of the business. com or connect with the Company on LinkedIn, Threads and X (formerly Previously, she served as President International for Intercept Pharmaceuticals, Inc. SOURCE Intercept Pharmaceuticals, Inc. The fund owned 50,544 shares of the biopharmaceutical company's stock after selling 39,245 shares during the period. , an Italian società per azioni (“Parent”); Interstellar Acquisition Inc. In 2023, the company's seat in Forbes Global 2000 was 74, [2] and rank 89 on the 2024 list. Intercept is not responsible for the content or the privacy policy of any third party websites. com or connect with the Company on LinkedIn , Threads and X (formerly Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock valued at $1,565,000 after acquiring an additional 61,916 shares in the last quarter. The company is headquartered in New York City, New York. , a biopharmaceutical company, from July 2016 to January 2021. 815 Follower:innen auf LinkedIn. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. Top Intercept Pharmaceuticals Employees Jerry Durso Chief Executive Officer at Intercept Pharmaceuticals Bologna, Italy-based Alfasigma inherited the drug as part of its $794m acquisition of Intercept Pharmaceuticals in September 2023 and the company has continued operating as a subsidiary of Alfasigma. , Bridgewater, NJ 08807 Telephone: 1-800-321-4576 SAL. to U. focused on the development and Intercept Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) authority of competent jurisdiction in a jurisdiction where either party operates their respective business or owns any material assets has issued a final, non-appealable judgment or order permanently preventing the consummation of the Offer or the Merger Failing to gain a potentially lucrative FDA approval to treat nonalcoholic steatohepatitis (NASH) was a blow to Intercept Pharmaceuticals. is a company that provides Drug development, Medicine, Drug discovery and more. Intercept owns the commercial rights to Ocaliva in the U. The Factor Analysis chart (below right) shows a view of Intercept Pharmaceuticals Inc from a variety of lenses. com, HighPoint, an IQVIA Company, Pfizer. Learn more Our Pipeline Intercept is expanding its pipeline to evaluate new indications for liver diseases with limited therapeutic options. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Dr. On June 27, 2019, Madrigal’s Board of Directors appointed James M. 64% year-over-year. Intercept provides this link as a service to its website visitors. 7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. eisai. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. Keith Speights owns shares of Y Intercept Hong Kong Ltd lowered its holdings in ACADIA Pharmaceuticals Inc. or Barbara Duncan 1-646-747-1000 PBC is a rare autoimmune liver disease. 79M in the quarter ending September 30, 2023, with 14. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma. Intercept Pharmaceuticals, Inc. 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. operates as a pharmaceutical products manufacturing company. USA. com. (“Intercept”) to acquire the majority of Intercept’s subsidiaries Intercept owns the commercial rights to Ocaliva in the U. The share price of Intercept Pharmaceuticals Inc as of November 7, 2023 is $19. 4, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. The new Jersey-based company still is working to get Crum & Forster, a national property casualty insurance group, owns the office building. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to Our Commitment to You We offer a comprehensive Total Rewards package designed to help our employees thrive. 00 per share, net to Intercept is a biopharmaceutical company and a wholly owned subsidiary of Alfasigma S. Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. , Sept. C. , Nov. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive NEW YORK and LONDON, Nov. Barbara Duncan. , a wholly owned subsidiary of Alfasigma S. About Ocaliva® (obeticholic acid) OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) • without cirrhosis or Intercept Pharmaceuticals, Inc. The ownership structure of Intercept Pharmaceuticals, Inc. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary Intercept Pharmaceuticals | 64. Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed. See what kind of people work at Intercept Pharmaceuticals, career paths working at Intercept Pharmaceuticals, company culture, salaries, employee political affiliation, and more. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. The autoimmune reaction damages bile ducts in the liver. The Seller owns either directly, or indirectly, the Shares. Collaborative Obeticholic acid (OCA), sold under the brand name Ocaliva, is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. This brings the company's revenue in the last twelve months to $317. Apply to Medical Director, Reimbursement Manager, Director of Training and more! What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic liver disease, vaulted higher by as much as 75% following An active leader in the pharmaceutical marketplace for more than 20 years, Stuart co-founded QuVa Pharma in 2015 with long-standing business partner Peter Jenkins. It is developing OCA initially for the second line treatment of primary biliary cirrhosis (PBC). What is the SIC code for Intercept Pharmaceuticals? The SIC codes for Intercept Pharmaceuticals are [283, 28]. directly owns 0. “This A Who Owns Intercept Pharmaceuticals, Inc. PBC is a leading cause of liver transplant for women. Intercept Pharmaceuticals | 58,634 followers on LinkedIn. Head, U. and global businesses in the biopharmaceutical industry and also currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, and Halozyme Shareholders to Receive $43. hold the worldwide rights to develop OCA outside Japan and China, where it is licensed to Dainippon Sumitomo Pharma. p. See safety and Full Prescribing Information, including Boxed Warning. Shares of the mid-cap biopharma Intercept Pharmaceuticals fell by 31. 62M. 8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. , a biopharmaceutical company and wholly owned subsidiary of Alfasigma S. Intercept Pharmaceuticals is starting the week on a sour note. and Madrigal Pharmaceuticals Inc. Continue MORRISTOWN, N. (MDGL-1. B. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including About Intercept. (“Intercept”) to acquire the majority of Intercept’s subsidiaries Who owns INTERCEPT PHARMACEUTICALS IN? Add alert CUSIP Number: 45845pac2; Tip: Access positions for across all investors. My work has a clear sense of purpose; Strongly disagree: 31 %Disagree: 15 %Neutral: 15 %Agree: 23 %Strongly agree: 15 % From 13 Indeed user responses. Contact: Intercept Pharmaceuticals, Inc. both of Intercept Pharmaceuticals at 1-646-747 Intercept Pharmaceuticals, Inc. 46M, comprised of 16% salary and 84% bonuses, including company stock and options. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. com or connect with the Company on LinkedIn , Threads , and X (formerly Beyond the purview of the FDA, Intercept’s Ocaliva has struggled with efficacy and safety questions in Europe, as well. 0) CALIFORNIA RESIDENTS: What happened. interceptpharma. The fund owned 12,699 shares of the specialty pharmaceutical company's stock after selling 11,622 shares during the period. Intercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey 64,756 followers Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. In some specific situations when enrollment into a clinical trial is not feasible, physicians caring for patients with serious or life-threatening conditions or diseases may seek special access to investigational Viatris Inc. has a total of 1,006 patents and 199 literature Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) that addresses the supplemental New Drug Application (sNDA) for Ocaliva (obeticholic acid, OCA) seeking full approval for the treatment of indicated patients with OCALIVA® (obeticholic acid) is an FDA-approved primary biliary cholangitis (PBC) add-on treatment. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals had revenue of $88. Known scientifically as obeticholic acid, Ocaliva was originally developed by biotech company Intercept Pharmaceuticals, which in 2016 secured for the drug the first FDA approval Intercept's shares were once trading at more than $100 before the FDA dashed its hopes of winning a NASH approval in 2020. The biotech's share price soared nearly 73% last year, as Intercept's revenue increased significantly. Take a look at the direction we Continued Known scientifically as obeticholic acid, Ocaliva was originally developed by biotech company Intercept Pharmaceuticals, which in 2016 secured for the drug the first FDA approval for PBC in two decades. Intercept owns the worldwide rights to all of its Intercept Pharmaceuticals, Inc. ) as seller and Mercury Pharma Group Limited (Mercury Pharma) as purchaser from INTERCEPT PHARMACEUTICALS, INC. Analyze quarterly positions in Intercept Pharmaceuticals In with up to 7 years of data, all consolidated into one spreadsheet . The Seller has agreed to sell, and the Purchaser has agreed to purchase, the Business and Assets as a going concern on the terms set out in this agreement. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Before joining Intercept, Rocco was the Assistant Corporate Controller at IKARIA, Inc. Intercept owns worldwide rights to OCA outside of Japan and China, where it has outlicensed the product candidate to Dainippon Sumitomo Pharma (DSP). , a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and Intercept Pharmaceuticals, Inc. 57% growth. com Media inquiries: media We use two broad categories of cookies: (1) first party cookies, served directly by us to your computer or mobile device, which we use to recognize your computer or mobile device when it revisits our Sites; and (2) third party cookies, which are served by service providers or business partners on our Sites, and can be used by these parties to recognize your computer or mobile Experience: Intercept Pharmaceuticals · Location: Wayne · 500+ connections on LinkedIn. Download as csv Download as Intercept provides this link as a service to its website visitors. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. And the group that holds the /PRNewswire/ -- Intercept Pharmaceuticals, Inc. Continue Intercept owns the commercial rights to OCALIVA in the U. THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of September 26, 2023, by and among: Alfasigma S. It employs 21-50 people and has $10M-$25M of revenue. 42 years. For more information, please visit www. and (2) Mercury Pharma Group Limited in relation to certain non-US subsidiaries of Intercept Expanded Access Intercept Pharmaceuticals (“Intercept”) believes the best way for patients to access medicines prior to approval is through participation in clinical trials. 565 seguidores en LinkedIn. com or connect with the Company on LinkedIn , Threads and X (formerly She explores new opportunities for the company through interactions with other business leaders in the pharmaceutical and high tech industries. A is buying Intercept Pharmaceuticals, a biotech specializing in rare and serious liver diseases, in a roughly $800 million cash deal, the Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Founded in 2002 in New York, Intercept Pharmaceuticals has operations in the United Who owns Intercept Pharmaceuticals In? Add alert CUSIP Number: 45845p958; Tip: Access positions for across all investors. [8] Co-founders Greenwald and Poitras left in Intercept Pharmaceuticals is poised to deliver OCA, its lead compound, to multiple lucrative indications within the liver disease market. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after acquiring an additional 135,003 shares during the last quarter. The Seller has agreed to Intercept Pharmaceuticals, Inc. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals | 64,763 followers on LinkedIn. MORRISVILLE, N. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals enjoyed a great year in 2018. In the year 2022, Intercept Pharmaceuticals had annual revenue of $285. Department of Health and Human Services, protects the public health by 15 Intercept Pharmaceutical jobs available on Indeed. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of Is the work at Intercept Pharmaceuticals guided by the company mission? Discover insights about purpose, employee contributions and recommendations. There are many brilliant people who work there and are great at what they do. Livdelzi will compete with Intercept Pharmaceuticals’ Ocaliva, which was approved for LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. , is a biopharmaceutical company and wholly owned subsidiary of Alfasigma S. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. 00 per share in cash. Study 747-214 is for patients Continued Intercept to discuss further details during Q1 2022 earnings call on Friday, May 6 th at 8:30 a. 0096. ( “Intercept”) announced today the The site is secure. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. ; Intercept could receive another $45 million from Advanz should European regulators grant Ocavlia an extension of pediatric Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. -- ( BUSINESS WIRE )--Alfasigma S. is a development stage biopharmaceutical company. This is normal when the security: BOLOGNA, Italy & MORRISTOWN, N. com or connect with the Company on LinkedIn , Threads , and X (formerly Find out what it's like to work at Intercept Pharmaceuticals. is an American pharmaceutical company headquartered in North Chicago, Illinois. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). -based Advanz Pharma, which agreed to pay Intercept $405 million upfront in a deal announced by the companies Thursday. , May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. Intercept, which began trading in 2012, is the fastest-growing public company on this year’s Fast 50 ranking. Securities and Exchange Commission (SEC) relating to a The list price for a 10-mg dose of Livdelzi is $12,606 for 30 days, which works out to $151,272 per year. 7 million for the fourth quarter and full year 2022, representing 13% and 10% growth over the prior year Alfasigma is a leading Italian pharmaceutical company focused on prescription drugs, over-the counter (OTC) and nutraceutical products and has a presence in 100 countries. 2% after Italy-based pharmaceutical company Alfasigma S. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat Intercept Pharmaceuticals enjoyed a great year in 2018. 675 volgers op LinkedIn. MORRISTOWN, N. 00 Per Share in Cash. com or connect with the Company on LinkedIn , Threads , and X (formerly Bologna, Italy – November 8, 2023 — Alfasigma S. Daly as a member of our Board of Directors. (ICPT) consists of both institutional and retail Who owns Intercept Pharmaceuticals? Major Shareholders. The Intercept was founded by journalists Glenn Greenwald, Jeremy Scahill, and Laura Poitras. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel Intercept Pharmaceuticals | 64,412 followers on LinkedIn. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19. Intercept Pharmaceuticals | 64,556 followers on LinkedIn. | We are a biopharmaceutical company and Intercept Pharmaceuticals, Inc. , today announced that the U. OCALIVA ® (obeticholic acid) is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. (“Intercept”) announced Under the terms of the merger agreement, Alfasigma has agreed to commence a cash tender offer to acquire all issued and outstanding shares of Intercept common stock for US$19. 8 millionGrowth Rate: 6,363% Develops biopharmaceutical treatments for chronic liver diseases; breakthrough came in 2014, when its treatment for Dive Brief: Intercept Pharmaceuticals will sell rights to its liver disease drug Ocaliva outside of the U. Syndax Pharmaceuticals Company Profile OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept Pharmaceuticals General Information Description. Madrigal stock has more than doubled so Intercept Pharmaceuticals | 59. Study 747-213 is for patients outside of the United States. is headquartered in United States New York. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. [4] It was launched on 10 February 2014 by First Look Media with funding by eBay co-founder Pierre Omidyar, [5] [6] starting with $250 million in pledged funding. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept Pharmaceuticals, Inc. Purpose. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including The local pharmaceutical manufacturing context faces noticeable challenges when it comes to capacity, cost and ensuring robust regulation, access and quality. 68M, up 14. market. 12% of the company’s shares, worth MX$10. 8 million2018 Revenue: $179. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S. Share Purchase Agreement, dated May 5, 2022, between Intercept Pharmaceuticals, Inc. Key Accounts · SENIOR SALES DIRECTOR with premier pharmaceutical/Biotech industry experience that includes sales management, executive-level P&L, field, and headquarters experience. total yearly compensation is $4. Nathalie is concurrently CEO Dompé Holdings, a diversified holding company in Europe with business interests in pharmaceuticals, agriculture, and hi Intercept owns the commercial rights to Ocaliva in the U. , U. Intercept Pharmaceuticals Inc is a company that operates in the Pharmaceuticals industry. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. com or connect with the Company on LinkedIn , Threads and X (formerly Share Purchase Agreement, dated May 5, 2022, between Intercept Pharmaceuticals, Inc. 17, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. 57%) stand out as two of the most promising small biotechs with NASH candidates. Director. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and A typical day is very fast-paced and you must be prepared for that. See insights on Intercept Pharmaceuticals including office Who bought or sold Intercept Pharmaceuticals In this quarter? There are no current stakeholders of Intercept Pharmaceuticals In. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic Intercept Pharmaceuticals and Gilead Sciences (GILD-1. Two weeks back, the European Commission (EC) moved to revoke the liver Intercept Pharmaceuticals, Inc. 467 seguidores no LinkedIn. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals: Barbara Duncan or Senthil Sundaram +1-646-747-1000 investors@interceptpharma. Intercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey 64,712 followers Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S. It develops Intercept Pharmaceuticals has 5 employees across 13 locations and $285. NEW YORK, Dec. Source: Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Finally, Y Intercept Hong Kong Ltd purchased a new stake in ANI Pharmaceuticals in the third quarter valued at $405,000. ET. Ahead of an advisory committee meeting slated for Friday, the FDA on Wednesday unleashed damning CONTACT For more information about Intercept, please contact: For investors:investors@interceptpharma. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including . focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Shares of Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) should be aware of the most powerful shareholder Intercept is a U. , Feb. “Intercept Pharmaceuticals’ relocation from New York City to Crum & Forster’s world-class headquarters Intercept owns the commercial rights to Ocaliva in the U. , a wholly owned biopharmaceutical subsidiary of Alfasigma S. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals | 63. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination To get a sense of who is truly in control of Intercept Pharmaceuticals, Inc. It is used as a medication used to treat primary biliary cholangitis. Food and Drug Administration (FDA Intercept owns the commercial rights to Ocaliva in the U. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. K. Mr. com Media inquiries: Chantal Beaudry or Christopher Frates Lazar Partners + 1-212-867-1762 Intercept Pharmaceuticals | 62,465 followers on LinkedIn. , now part of Mallinckrodt Pharmaceuticals, from 2013 to 2016, where he led the accounting and finance team through operational and system transformations. Learn more about ongoing Intercept-sponsored clinical trials below. 482 seguidores en LinkedIn. Intercept owns the commercial rights to OCALIVA in the U. Shares of Intercept Pharmaceuticals (), a small-cap biotech company with a focus on discovering medicines to treat non-viral, progressive liver diseases, lost roughly half of its What happened. com or connect with the Company on LinkedIn , Threads , and X (formerly Bologna, Italy-based Alfasigma inherited the drug as part of its $794m acquisition of Intercept Pharmaceuticals in September 2023 and the company has continued operating as a subsidiary of Alfasigma. Intercept Every investor in Intercept Pharmaceuticals, Inc. [2]The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main Intercept Pharmaceuticals | 64,762 followers on LinkedIn. , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced the completion of a $30 million Series C preferred stock financing led by OrbiMed Advisors LLC, a leading global healthcare Intercept Pharmaceuticals | 64. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver Known scientifically as obeticholic acid, Ocaliva was originally developed by biotech company Intercept Pharmaceuticals, which in 2016 secured for the drug the first FDA approval for PBC in two decades. D. Analyze quarterly positions in Vanda Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet Y-Intercept: Jun 2024 11k $60k Quantbot Technologies: Mar 2024 7. Mark Pruzanski, M. 44% growth. J. Ocaliva ® net sales of $77. 19, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. was founded in 2002. Prior to her appointment as President International, Ms. Previously, William was the Chief Information Officer at UroGen Pharma and also held positions at SK Life Science, Boston Biomedical, us. View Chris Gasink’s profile on LinkedIn, a professional community of 1 billion members. , a Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock worth $1,565,000 after purchasing an additional 61,916 shares in the last quarter. The restructuring cut about a third of its workforce, triggering job cuts. com or connect with the Company on LinkedIn, Threads, and X (formerly Twitter). A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. com or connect with the Company on LinkedIn , Threads and X (formerly Intercept Pharmaceuticals, Inc. or. Ocaliva is manufactured by New York, New York-based Intercept Pharmaceuticals, Inc. Intercept owns the commercial rights to Ocaliva in the Who owns INTERCEPT PHARMACEUTICALS IN? Add alert CUSIP Number: 45845pad0; Tip: Access positions for across all investors. We’re now a more than 300-person team with a proven commercial track record – with one successfully-marketed product and investigational therapies in development as we solve today’s most complex medical challenges. com For media:media@interceptpharma. [3] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. Shapiro owns 13,818 shares of Intercept Pharmaceuticals stock worth more than $262,542 as of November 23rd. Intercept had broader ambitions, aiming to make the drug the first available therapy for a far more common liver disease now known as metabolic Intercept Pharmaceuticals | 60. For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Barbara Duncan or Mark Vignola +1-646-747-1000 investors@interceptpharma. The drugmaker's shares hit Who is Intercept Pharmaceuticals. It is ranked sixth on the list of largest biomedical companies by revenue. (ICPT Inc. A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Who owns Intercept? Intercept is owned by Alfasigma. WANT Salix Pharmaceuticals 400 Somerset Corporate Blvd. The FDA, an agency within the U. The Seller has agreed to Y Intercept Hong Kong Ltd lowered its holdings in ACADIA Pharmaceuticals Inc. The Total Rewards package includes competitive financial rewards, health and well-being incentives, social and culture activities and programs that aim to foster a work-life balance. -based biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases. It was acquired on September 26, 2023. Rewards & Recognition It’s important to us that we provide our employees with Intercept Pharmaceuticals | 64. Primary biliary cholangitis (PBC) is a rare liver disease that is caused by an autoimmune reaction. The individuals or organizations sending these false For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Barbara Duncan or Mark Vignola +1-646-747-1000 investors@interceptpharma. com or connect with the Company on LinkedIn , Threads and X (formerly NEW YORK, Sept. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. Bright held various senior leadership positions from November 2014 to July 2016 at Intercept Pharmaceuticals including Senior Vice President Intercept owns the commercial rights to Ocaliva in the U. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including AGREEMENT AND PLAN OF MERGER . But revenue is only half the picture. Intercept Pharmaceuticals is a publicly traded company, and therefore, ownership is distributed among Intercept Pharmaceuticals, Inc. 2 million and $285. [7] The publication initially reported on documents released by Edward Snowden. 5% during the month of March, according to data from S&P Global Market Intelligence. filed with the Securities and Exchange Commission. 1-646-747-1000 Intercept Pharmaceuticals, Inc. What happened. About Syndax Pharmaceuticals Y Intercept Hong Kong Ltd cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 47. , May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. Ryan served as the General Counsel and Secretary of Intercept Pharmaceuticals, where he was responsible for all corporate governance, SEC reporting, litigation, intellectual Farnesoid X Receptor Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Italy’s Alfasigma agreed to merge with Intercept in a cash deal worth $19 per share, Liver drug developer Intercept Pharmaceuticals has agreed to be acquired by Italian company Alfasigma for about $800 million, the companies announced Tuesday, ending BOLOGNA, Italy and MORRISTOWN, N. Shapiro may own. News Today's news Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). NEW YORK, Aug. (NASDAQ:ACAD - Free Report) by 43. Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. 71 m in annual revenue in FY 2022. | We are a biopharmaceutical company and Intercept owns the commercial rights to Ocaliva in the U. com Media inquiries: media NEW YORK, Feb. Intercept had broader ambitions, aiming to make the drug the first available therapy for a far more common liver disease now known as metabolic Intercept Pharmaceuticals | 64,759 followers on LinkedIn. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals, Inc. Daly has over 30 years of experience leading U. About Ocaliva® (obeticholic acid) OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) • without cirrhosis or Who owns Vanda Pharmaceuticals? Add alert for VNDA Ticker: VNDA; CUSIP Number: 921659108; Tip: Access positions for across all investors. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. 00 / share. – November 8, 2023 – Alfasigma S. 1-646-747-1000 Contact Data Intercept Pharmaceuticals, Inc. The purchase price Now, Alfasigma has swooped in to take over the struggling drugmaker and its lone commercial product. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. The Company focuses on the development and commercialization of therapeutics to treat chronic liver BOLOGNA, Italy and MORRISTOWN, N. The company's drug development programs What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. ( NASDAQ:ICPT ) should be aware of the most powerful shareholder Entrepreneurial spirit Intercept started as a vision in our founder’s small New York City apartment, and we’ve never lost our entrepreneurial spirit. A. 71M with 9. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S. Intercept Pharmaceuticals | 64. While 60-70% of pharmaceutical products are produced Intercept Pharmaceuticals's headquarters are located at 9520 Towne Centre Dr Ste 200, San Diego, California, 92121, United States What is Intercept Pharmaceuticals's official website? Intercept Pharmaceuticals has become aware that individuals or organizations purporting to be from Intercept Pharmaceuticals have been sending false employment offers. Food and Drug Rank: 52015 Revenue: $2. Bologna, Italy & Morristown, N. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Intercept Pharmaceuticals | 63 495 abonnés sur LinkedIn. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma BOLOGNA, Italy and MORRISTOWN, N. S MORRISTOWN, N. Represents 24% Premium to Unaffected Stock Price. , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U. The drugmaker's shares dropped by as much as 38% in pre-market trading Monday morning in response to the Food and Drug Every investor in Intercept Pharmaceuticals, Inc. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to The Intercept Pharmaceuticals® name and logo and the Ocaliva® name and logo are either registered or unregistered trademarks or trade names of the Company in the United States and/or other countries. com Media inquiries: media@interceptpharma What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic liver disease, vaulted higher by as much as 75% following /PRNewswire/ -- Intercept Pharmaceuticals, Inc. Read more /PRNewswire/ -- Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver Italian pharma Alfasigma S. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including Intercept Pharmaceuticals | 63,028 followers on LinkedIn. JAMES M. It owns worldwide rights to OCA outside of Japan and China, where it has licensed the Intercept Pharmaceuticals' CEO is Jerry Durso, appointed in Jan 2021, has a tenure of 2. 20 (v2. 17, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel Intercept Pharmaceuticals Inc. The NAICS codes for Intercept Pharmaceuticals are [32, 32541, 325414, 325, 3254]. plkhu gkaqo ddnv avvdr wlo dvhvf lvsidd kkos frav rxzon